All In Biotech

NDA 206976 · Ibsa Inst Bio

Licart

Diclofenac Epolamine · Topical

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Dec 19, 2018

Approved uses

2

Original approval plus efficacy supplements

Registered trials

11

3 Phase 3, 0 recruiting

FAERS reports

701

264 serious, 32 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SERIOUS CARDIOVASCULAR and GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR and GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use ( 5.1 ) LICART is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. ( 4 , 5.1 ) NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease...

What it is approved for

From the label in effect Nov 2, 2026.

LICART is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. LICART contains diclofenac epolamine, which is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older ( 1 )

Mechanism: Diclofenac has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of diclofenac, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro. Diclofenac concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because diclofenac is an inhibitor of prostaglandin...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 27, 2026 Supplement 18 · Efficacy LabelLetter
  • Dec 19, 2018 Original approval · Type 3 - New Dosage Form and Type 4 - New Combination LabelLetterReview
1 products under this application
  • LICART · DICLOFENAC EPOLAMINE 1.3% · SYSTEM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Diclofenac Epolamine" as an intervention, any sponsor and status, largest first.

All 11 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug hypersensitivity183
  • drug ineffective105
  • pain53
  • off label use41
  • congenital anomaly34
  • fatigue33
  • malaise30
  • headache29
  • diarrhoea28
  • dyspnoea28
  • foetal exposure during pregnancy26
  • nasopharyngitis26

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20071
20101
20112
201221
201320
201426
201538
201627
201726
201866
2019103
202072
202158
202257
202336
202443
202571
202632

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Licart (Diclofenac Epolamine)

2024 spending

$7.9M

Beneficiaries

2,673

9,198 claims

Per beneficiary

$2,940

$24.24 per unit

View as table
YearSpending
2020$11,176
2021$1,776,088
2022$6,975,410
2023$8,661,117
2024$7,858,815

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 26 on PubMed

Sponsor: Ibsa Inst Bio

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.